0000899243-20-015877.txt : 20200609
0000899243-20-015877.hdr.sgml : 20200609
20200609210805
ACCESSION NUMBER: 0000899243-20-015877
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200605
FILED AS OF DATE: 20200609
DATE AS OF CHANGE: 20200609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cummings Keith Lamont
CENTRAL INDEX KEY: 0001809204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39303
FILM NUMBER: 20953344
MAIL ADDRESS:
STREET 1: C/O PLIANT THERAPEUTICS, INC.
STREET 2: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001746473
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474272481
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-481-6770
MAIL ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-05
0
0001746473
PLIANT THERAPEUTICS, INC.
PLRX
0001809204
Cummings Keith Lamont
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
Common Stock
2020-04-30
4
M
0
19300
2.08
A
19300
D
Common Stock
2020-06-05
4
C
0
3821
A
23121
D
Series C Preferred Stock
2020-02-28
4
A
0
27322
13.0845
A
Common Stock
3821
27322
D
Stock Option (right to buy)
6.22
2020-03-31
4
A
0
42841
0.00
A
2030-03-30
Common Stock
42841
42841
D
Stock Option (right to buy)
2.08
2020-04-30
4
M
0
19300
0.00
D
2029-01-23
Common Stock
19300
206188
D
Series C Preferred Stock
2020-06-05
4
C
0
27322
0.00
D
Common Stock
3821
0
D
On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.
The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date.
1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date
25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/ Anthony Franks, attorney-in-fact
2020-06-09